DiaGen AI Partners With Nasdaq:MEDS to Discover Novel Cancer Targets and Develop Anti-Cancer Peptide Pipeline
DiaGen AI, Inc. announced a partnership with Nasdaq:MEDS focused on discovering novel cancer targets and developing an anti-cancer peptide pipeline, according to the company.
As part of the arrangement, DiaGen earned a 630,000 share equity stake in Nasdaq:MEDS, equivalent to 9.9% of the company, valued currently at over USD $400,000, according to the company.
Key Highlights
- DiaGen AI, Inc. has partnered with Nasdaq:MEDS to discover novel cancer targets and develop an anti-cancer peptide pipeline, according to the company.
- DiaGen earned a 630,000 share equity stake in Nasdaq:MEDS, according to the company.
- The equity stake is equivalent to 9.9% of Nasdaq:MEDS, according to the company.
- The stake is valued currently at over USD $400,000, according to the company.
Strategic Context
According to the company, DiaGen and DataMEDS subsidiary Helomics will first validate fifteen cytotoxic peptides, identified with the methodology published in Nature Communications and implemented in DiaGen’s CYPRESS platform, on primary breast cancer biopsies, including triple negative breast cancer. In published testing the peptides were at least 5.5-fold less toxic to normal human blood cells than to cancer cells, but their mechanism of action has not been established, and the companies will work jointly to determine it. If a therapeutic target is found, they will test whether it applies to other cancers in the Helomics Biobank, which holds more than 70,000 tumor biopsies. DiaGen will build a small molecule candidate library with its BLACKCOMB platform, Helomics will run preclinical in vitro and primary tumor validation, and the two will confirm candidate selection in breast cancer animal models. The companies will jointly own the resulting intellectual property and plan to partner the targets and candidates with pharmaceutical companies or launch a joint venture. The agreement includes a reciprocal share exchange, with DataMEDS issuing 630,000 common shares to DiaGen and DiaGen issuing DataMEDS 9.9% of its fully diluted common shares. DataMEDS will contribute up to 50% of compute expenses, DiaGen will fund wet lab hard costs as milestones are met, and total value is expected to reach $1.5 million in cash and in-kind contributions through project milestones.
About DiaGen AI, Inc.
Headquartered in Vancouver, DiaGen AI Inc. is developing a diverse pipeline of AI-powered tools for small molecule and peptide discovery, diagnostics, and delivery. Using its proprietary generative AI Blackcomb and Cypress Protocols, DiaGen aims to de-risk, accelerate, and create value across the global traditional SME drug discovery sector, advancing precision medicine and impacting global human longevity. DiaGen’s research has been accepted at NeurIPS, the premier machine learning conference, and the company is a graduate of the Creative Destruction Lab at the University of Washington among other world-wide partnerships.
Disclaimer and Forward-Looking Statements
The information contained herein is provided by ArcStone Financial Pulse Inc. ("ArcStone Financial Pulse"), a subsidiary of ArcStone Securities and Investments Corp. ("ArcStone"), for informational purposes only. It is not, and under no circumstances should it be construed as, an offer to sell or a solicitation of an offer to buy any securities or other financial instruments in any jurisdiction. This content is not a research report within the meaning of FINRA Rules 2241 or 2242 and does not constitute a research report under any applicable securities laws.
Certain statements contained herein may constitute "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements are based on current expectations, estimates, and assumptions that involve known and unknown risks and uncertainties which may cause actual results or developments to differ materially from those expressed or implied. These statements often include words such as "anticipate," "believe," "expect," "intend," "may," "plan," "project," "should," "target," or similar expressions. Readers are cautioned not to place undue reliance on such statements, which speak only as of the date made. Except as required by law, ArcStone undertakes no obligation to update or revise any forward-looking information.
This content is not intended as investment advice or a recommendation to buy or sell any security and does not take into account the investment objectives, financial situation, or needs of any individual. Investors should consult their own professional advisors before making any investment decisions.
ArcStone Securities and Investments Corp. is not a registered broker-dealer and does not provide investment advice or recommendations. All registrable activities in the United States are conducted through ArcStone Securities, LLC (CRD# 306029) and/or Kingswood Capital Partners, LLC (CRD# 288898), both FINRA-registered broker-dealers, members SIPC. ArcStone Canada Inc. is not registered as a dealer in any Canadian jurisdiction; registrable dealing activities in Canada are conducted through appropriately registered affiliates.
ArcStone Kingswood is a DBA Office of Supervisory Jurisdiction (OSJ) of Kingswood Capital Partners, LLC (Member FINRA/SIPC) under which registered representatives of ArcStone Securities, LLC (Member FINRA/SIPC) and registered representatives of Kingswood Capital Partners, LLC conduct joint capital markets and investment banking activities. ArcStone Securities, LLC and Kingswood Capital Partners, LLC are parties to a written agreement governing the sharing of fees on transactions in which registered representatives of both firms participate. All securities transactions and investment banking services described in this article are conducted exclusively through ArcStone Securities, LLC and/or Kingswood Capital Partners, LLC; "ArcStone Kingswood" itself is not a registered broker-dealer or separate legal entity.
ArcStone Financial Pulse Inc. is owned by the same parent entity (ArcStone Securities and Investments Corp.) that owns ArcStone Securities, LLC. This common ownership, together with the joint operating relationship between ArcStone Securities, LLC and Kingswood Capital Partners, LLC under the ArcStone Kingswood DBA OSJ banner, represents a structural conflict of interest. The issuer featured in this article (the "Company") may be a current or former client of ArcStone or any of its subsidiaries and affiliates. Where ArcStone or its subsidiaries and affiliates have received or have been promised consideration for services provided to the Company, such consideration may include cash, stock, stock options, warrants, and/or Restricted Stock Units (RSUs) for the provision of corporate advisory, investor relations, digital media, or capital markets consulting services. This relationship represents a potential conflict of interest, as ArcStone may be perceived to have an incentive to present the Company in a favorable light. The principals, directors, officers, employees, and related entities of ArcStone and its affiliates may, from time to time, own, buy, or sell securities or derivatives of the Company or its affiliates.